Adam Raskin, MD
Cardiovascular Disease · Fairfield, OHNPI 1225264914
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (34.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Inari Medical, Inc. at 45.7% of the total. Reporting peaked in 2023 at $39,368 and has fallen 78.2% since, to $8,570 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,058 payments — averaging $104.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$51K
- Imperative Care, Inc$27K
- Abiomed$7K
- Truvic Medical, Inc.$7K
- Abbott$6K
- Boston Scientific$2K
- plus $11K from 42 others
Across 111 payments — averaging $1958.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Inari Medical, Inc.$156K
- Imperative Care, Inc$61K
- Abiomed$148
What the payments were for
- Consulting fees$32,61729%
- Speaking & faculty fees$32,20029%
- Travel & lodging$7,9387%
- Food & beverage$37,75134%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CT THROMBECTOMY SYSTEM KIT$51,271
- FLOWTRIEVER CATHETER, S$43,813
- ZOOM 88-T LARGE DISTAL PLATFORM$15,250
- SYMPHONY CATHETER$5,434
- Impella$2,789
- Omnilink Elite vascular stent system$1,765
- PRODIGY CATHETER$1,424
- Resolute$816
- FlowTriever$449
- ClotTriever$449
- XACT$449
- LifeSPARC$442
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$316
- Barostim Neo System$300
- Absolute Pro vascular stent system$280
- Diamondback Peripheral$257
- AngioVac$257
- XARELTO$226
- Indigo$207
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$186
How this compares
$110,621 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 290 | $292,186 |
| XareltoRivaroxaban | 178 | $191,401 |
| EntrestoSacubitril/Valsartan | 113 | $117,229 |
| JardianceEmpagliflozin | 38 | $38,677 |
| BrilintaTicagrelor | 30 | $15,544 |
| Repatha SureclickEvolocumab | 23 | $13,245 |
| Praluent PenAlirocumab | 11 | $5,282 |
| Metoprolol Succinate | 341 | $3,724 |
| Amiodarone Hcl | 70 | $3,076 |
| Atorvastatin Calcium | 372 | $2,903 |
| Rosuvastatin Calcium | 115 | $1,495 |
| ClopidogrelClopidogrel Bisulfate | 177 | $1,257 |
| Carvedilol | 177 | $1,236 |
| Nifedipine ErNifedipine | 36 | $1,151 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $99 | $292,186290 claims |
| Johnson & JohnsonXarelto | $1,277 | $191,401178 claims |
| NovartisEntresto | $1,035 | $117,229113 claims |
| Boehringer IngelheimJardiance | $406 | $38,67738 claims |
| AstraZenecaBrilinta | $431 | $15,54430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Fairfield
- Lynne WagonerFairfield$88K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.